This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A 52-week, multi-center, randomized, double-blind,...
Clinical trial

A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer�s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

Read time: 1 mins
Last updated:12th Sep 2007
To evaluate the safety and tolerability of repeated subcutaneous (s.c.) injections of 150?g CAD106 in patients with mild AD over the 52 weeks of the study.
Category Value
Study start date 2007-09-12

View full details